Form 4: Evoke Pharma CEO Matthew D'Onofrio Acquires Stock Options
SEC Form 4 Filing
Evoke Pharma's CEO, Matthew D'Onofrio, was granted stock options to purchase 64,840 shares of common stock.
Summary
- On August 7, 2024, Matthew J. D'Onofrio, CEO of Evoke Pharma Inc., acquired stock options for 64,840 shares.
- The exercise price of these options is $5.27 per share.
- The options vest over a three-year period, beginning 18 months after August 7, 2024, with full vesting on the third anniversary.
- The expiration date for these options is August 6, 2034.
Sentiment
Score: 7
Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management and shareholder interests.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management incentives with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the pharmaceutical industry.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants.
Stakeholder Impact
- Shareholders may view this positively as it aligns the CEO's interests with the company's long-term success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 08/07/2024 | Date of transaction: Matthew J. D'Onofrio acquired stock options. |
| 08/07/2024 | Vesting Commencement Date: 50% of options vest after 18 months, with the remaining vesting monthly over the following 18 months. |
| 08/06/2034 | Expiration Date: Stock options expire on this date. |
Keywords
stock options, Evoke Pharma, CEO, Matthew D'Onofrio, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.